Wealthfront Advisers’s Viking Therapeutics VKTX Stock Holding History

Wealthfront Advisers’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$422K	Buy	10,822 +1,001	+10%	+$32.3K	﹤0.01%	916
2026 Q1	$320K	Sell	9,821 -2,500	-20%	-$80.4K	﹤0.01%	925
2025 Q4	$433K	Sell	12,321 -481	-4%	-$17K	﹤0.01%	848
2025 Q3	$336K	Buy	12,802 +2,754	+27%	+$82.2K	﹤0.01%	883
2025 Q2	$266K	Buy	10,048 +1,289	+15%	+$33.9K	﹤0.01%	890
2025 Q1	$212K	Buy	8,759 +3,786	+76%	+$120K	﹤0.01%	904
2024 Q4	$200K	Buy	+4,973	New	+$284K	﹤0.01%	895

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Wealthfront Advisers's VKTX Position: Q2 2026 in Review

Wealthfront Advisers increased its Viking Therapeutics (VKTX) stake by 10% in Q2 2026, buying an estimated $32.3K and bringing the position to 10,822 shares worth $422K. The position accounts for ﹤0.01% of the portfolio, ranked #916.

Wealthfront Advisers first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $433K in Q4 2025. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

Wealthfront Advisers held 10,822 shares of Viking Therapeutics worth $422K as of Q2 2026.
Wealthfront Advisers bought 1,001 Viking Therapeutics shares in Q2 2026, an estimated $32.3K.
Viking Therapeutics made up ﹤0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #916 holding.
Wealthfront Advisers first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
Wealthfront Advisers's Viking Therapeutics position peaked at $433K in Q4 2025.
436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.